Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

22 citing papers in PubMed.

1. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial.Schizophrenia bulletin · 2011
   Trial
2. Genomewide association for schizophrenia in the CATIE study: results of stage 1.Molecular psychiatry · 2008
   Trial
3. Cognitive Behavioural Therapy for Psychosis: A Health Technology Assessment.Ontario health technology assessment series · 2018
   Review
4. Adapting SugarWatch to manage metabolic syndrome in a partial hospitalization program: a feasibility study.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2015
   Article
5. Olanzapine-Induced Neutropenia.Mental illness · 2015
   Article
6. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies.The American journal of psychiatry · 2015
   Article
7. Atypical antipsychotic usage among Asian Americans and Pacific Islanders.Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health · 2014
   Article
8. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.PloS one · 2014
   Article
9. Comparative effectiveness of atypical antipsychotics in schizophrenia: what have real-world trials taught us?CNS drugs · 2012
   Review
10. Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.Psychopharmacology · 2011
    Article
11. No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition.American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics · 2010
    Article
12. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance.Behavioural brain research · 2010
    Article
13. Beyond the dopamine receptor: novel therapeutic targets for treating schizophrenia.Dialogues in clinical neuroscience · 2010
    Review
14. Clinical trial design: horses for courses.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2009
    Article
15. Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway.Molecular psychiatry · 2008
    Review
16. Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.PloS one · 2008
    Article
17. Do effectiveness ("real world") studies on antipsychotics tell us the real truth?European archives of psychiatry and clinical neuroscience · 2008
    Review
18. Are second generation antipsychotics a distinct class?Journal of psychiatric practice · 2008
    Review
19. rTMS strategies for the study and treatment of schizophrenia: a review.The international journal of neuropsychopharmacology · 2008
    Review
20. Who are the new users of antipsychotic medications?Psychiatric services (Washington, D.C.) · 2008
    Article

Corrections and comments

• Commented on by
  First- and second-generation antipsychotics: learning from CUtLASS and CATIE.2007
• Commented on by
  CUtLASS confirms CATIE.2007
• Comment on
  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.2005
• Comment on
  Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).2006

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as